Home - Clinical Trials Arena
WEBAstraZeneca eyes up transition to eco-friendly inhaler propellant. Results from AstraZeneca’s completed clinical studies will be shared with regulatory authorities by the end of this year. More themes. Artificial Intelligence.
Obesity: Six trials to watch over the next 12 months
WEBAbigail Beaney June 30, 2023. Here are some trials for obesity medications to watch over the next 12 months. Image credit: Zdenek Macat / Getty Images. The approval of Novo Nordisk ’s Wegovy in 2021 catapulted the landscape of obesity medications as companies race to develop other drugs which can provide higher levels of efficacy. Free ...
BeiGene spin-out Pi Health raises $30m to uptick cancer trial …
WEBMar 15, 2024 · Pi Health has launched on the clinical trial software-as-a-service (SaaS) market after completing a $30m Series A funding. The US company, created as a subsidiary of BeiGene three years ago, has developed a platform to help increase patient enrolment in cancer trials. Led by US venture capital firms …
POINT’s prostate cancer trial meets primary endpoint as Lilly’s …
WEBDec 19, 2023 · Eli Lilly first announced the potential acquisition of POINT in a deal worth $1.4bn in October. Credit: Michael Vi via ShutterStock. US-based Lantheus and POINT Biopharma have announced positive topline data from the Phase III trial investigating prostate cancer therapy 177Lu-PNT2002, as Eli Lilly extends its tender offer deadline.
Trials to watch: Four ALS drugs to keep an eye on
WEBApr 30, 2024 · Regimen F is a Phase II/III trial (NCT05740813) which will evaluate the safety and efficacy of a single study drug, ABBV-CLS-7262, in patients with ALS. ABBV-CLS-7262 has been developed in a partnership between Calico Life Sciences and AbbVie. Regimen F plans to enrol 300 patients with a primary completion date of September 2024.
Alzheimer's trials: How does donanemab compare to lecanemab?
WEBJan 13, 2023 · Already, 2023 is shaping up to be an eventful year in Alzheimer’s disease (AD) drug development. After the FDA’s approval of Eisai/Biogen’s Leqembi (lecanemab) on January 6, the AD field is now looking toward the upcoming approval decision for Lilly’s donanemab expected in May. Although both donanemab and lecanemab have similar therapeutic targets, the two AD antibodies employed ...
Labcorp partners with Hawthorne for decentralised clinical trials
WEBJan 11, 2024 · Labcorp, a laboratory services provider, has announced a strategic collaboration with Hawthorne Effect to create new service offerings that support decentralised clinical trials. Through this partnership, the companies will advance trial capabilities for biotech, pharma and medical device sponsors. The focus will be on improving patient ...
Trials to watch: CRISPR pipeline accelerates after milestone …
WEBJan 17, 2024 · Vor BioPharma is conducting another Phase I/II trial (NCT05984199) which is estimated to enrol 24 patients with relapsed or refractory AML post HCT. GlobalData’s analyst consensus forecast estimates VOR33 to generate $361m in sales in 2029. Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.
Moderna’s Phase III Covid-19 vaccine trial meets primary endpoints
WEBMar 27, 2024 · Moderna has announced positive interim results from the Phase III NextCOVE clinical trial, where its next-generation Covid-19 vaccine candidate, mRNA-1283, met the primary endpoints. The randomised, active-controlled, observer-blind trial included nearly 11,400 participants aged 12 years and above from the UK, US, and Canada.
Dermavant maps out atopic dermatitis filing after positive Phase III ...
WEBJan 12, 2024 · US-based pharmaceutical company Dermavant Sciences, a division of Roivant Sciences, has announced positive results from its Phase III development programme evaluating Vtama (tapinarof) cream for the treatment of atopic dermatitis. The development programme is made up of three studies that are evaluating the 1% Vtama cream in adults and ...
Skip to content